Study redefines how doctors measure COPD decline, spotting worsening before hospitalization
Researchers found that early warning signs of COPD deterioration — like increased inhaler use and symptom worsening — actually predict worse outcomes than traditional exacerbation measures alone. The finding could reshape how pharmaceutical companies design COPD trials and how insurers and health systems evaluate treatment effectiveness and patient risk.
Originaltitel: Clinical Meaningfulness of the Composite Endpoint, COPDCompEx, in Defining Exacerbations and Worsening of COPD: A Post Hoc Analysis of 4 Clinical Interventional Studies of COPD.
PURPOSE: COPDCompEx is a novel composite end point that includes moderate and severe exacerbation events (requiring oral corticosteroid and/or antibiotic use, or hospitalization), as well as acute worsening events (AWEs), defined as deteriorating chronic obstructive pulmonary disease (COPD) symptoms accompanied by a decline in peak expiratory flow (PEF; morning or evening) or an increase in reliever medication use. AWEs are generally self-managed and rarely reported in clinical trials. PATIENTS AND METHODS: In this post hoc analysis, patient data were obtained from 4 COPD clinical intervention studies and were pooled and grouped according to the occurrence of COPDCompEx events (exacerbations only, AWEs only, and mixed events). For each group, outcomes evaluated included: PEF, reliever medication use, COPD symptoms (ie, breathlessness, sputum, cough, and sleep), forced expiratory volume in 1 second (FEV RESULTS: All event types impacted PEF and reliever medication use, with AWEs having a greater effect than exacerbations (event-level data). The COPD symptoms were more pronounced for AWEs and mixed events than exacerbations; the return to baseline was slower for mixed events. Additionally, mixed events had a greater impact on FEV CONCLUSION: The COPDCompEx composite outcome includes patient-relevant AWEs that represent a clinically meaningful, patient-centric end point. The data highlight the relevance of COPDCompEx as a drug development tool that could improve clinical development in COPD treatments thereby achieving better outcomes for patients.